ABSTRACT
COVID-19 is a novel respiratory disease first identified in Wuhan, China, that is caused by the novel coronavirus, SARS-CoV-2. It has triggered a global pandemic of historic proportions. The government of the Philippines began its national vaccine drive on March 1, 2021, with the goal of vaccinating seventy million of its citizens by the end of the calendar year. To determine the optimum geographical distribution strategy in the Philippines for the limited supply of vaccines that is currently available, we developed and adapted a basic SIR model that allows us to understand the evolution of a pandemic when public health authorities are vaccinating two susceptible populations within a country with different vaccine rates. Our analysis with our 2SIR-VD model revealed that prioritizing vaccine deployment to the National Capital Region (NCR) of the Philippines minimized the number of COVID-19 cases in the country. We therefore recommend deploying 90% of the available vaccine supply to the NCR to mitigate viral transmission there. The remaining 10% would allow the rest of the archipelago to vaccinate all of their senior citizens, thus shielding this vulnerable population against severe disease and death from COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was utilized for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB approval or exemption was not needed for this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos